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Abstract
Background: Dimethyl sulfoxide (DMSO) is frequently used at a concentration of up to 95% in
the formulation of antiherpetic agents because of its properties as a skin penetration enhancer.
Here, we have analyzed the effect of DMSO on several parameters of Herpes Simplex Virus
replication.
Methods: Productive infection levels of HSV-1 were determined by plaque assay or by reporter
gene activity, and its DNA replication was estimated by PCR. Transcript levels were evaluated with
HSV-specific DNA micro-arrays.
Results: DMSO blocks productive infection in vitro in different cell types with a 50% inhibitory
concentration (IC50) from 0.7 to 2% depending upon the multiplicity of infection. The
concentration dependence exhibits a Hill coefficient greater than 1, indicating that DMSO blocks
productive infection by acting at multiple different points (mechanisms of action) with positive
cooperativity. Consistently, we identified at least three distinct temporal target mechanisms for
inhibition of virus growth by DMSO. At late stages of infection, DMSO reduces virion infectivity,
and markedly inhibits viral DNA replication. A third mode of action was revealed using an
oligonucleotide-based DNA microarray system for HSV. These experiments showed that DMSO
reduced the transcript levels of many HSV-1 genes; including several genes coding for proteins
involved in forming and assembling the virion. Also, DMSO markedly inhibited some but not all
early transcripts indicating a previously unknown mode for inhibiting the early phase of HSV
transcription-replication cycle.
Conclusion: These observations suggest that DMSO itself may have a role in the anti-herpetic
activity of formulations utilizing it as a dispersant.
Background
Herpes simplex virus-1 (HSV-1) is an enveloped double-
stranded DNA virus of humans, which has a broad host
range for animals and cell type. Although most of herpes
infections are mild, they can cause lethal encephalitis, par-
ticularly in infants. Indeed, herpes infections are a major
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An important characteristic of herpes virus is their ability
to establish latent infections in the neurons of sensory
ganglia innervating the site of initial infections (reviewed
in [2]). The virus can reactivate spontaneously or under
conditions of stress, causing recurrent infections in the site
of initial infections. For instance, reactivation of latent in-
fections in the trigeminal ganglia causes recurrent infec-
tion in the cornea leading to scarification [3–5]. This is a
major cause of blindness induced by infection in develop-
ing countries and a major reason for corneal transplanta-
tion treatments in developed countries.
While through latency, herpes can evade both the im-
mune surveillance and antiviral drug-therapy, inhibition
of acute replication during primary or reactivating infec-
tion through the intervention of anti-herpes drugs is of
significant importance. To develop more efficient antivi-
ral therapies it is essential to have an understanding as
comprehensive as possible of the mode of action of the
different antiviral agents as well as the possible action of
the vehicles used in their formulation. Recently developed
micro-array technology greatly facilitates the global anal-
ysis of a drug on the expression of most of the viral genes
and on a number of cellular genes [6].
Currently, the most widely used anti-herpetic agents are
nucleotide derivatives such as Acyclovir, adenine arabino-
side, Edoxidine, Idoxouridine and pencyclovir [7]. These
compounds block viral replication by inhibiting viral
DNA polymerase and thymidine kinase activities. Other
drugs with anti-herpetic potential include alpha and beta
interferons, ribonucleotide reductase inhibitors (tio-
cabonohydrazone), inhibitors of virus penetration (Tro-
mantadine) and other inhibitors of viral DNA polymerase
(Foscarnet).
Intravenous, oral and topical routes are common to ad-
minister different antiviral agents. In the case of skin infec-
tions, topical applications have several advantages,
including convenience and reduction of side effects. In ad-
dition, it is possible to obtain higher concentrations of the
antiviral drug at the locus of viral replication when the
drug is formulated with a skin penetration enhancer [8].
DMSO is one of the most frequently used skin penetration
agents for antiherpetic drugs and is generally used at a
concentration of up to 95% [9]. It has been used in the
formulation of Idoxouridne [10], adenine arabinoside,
Acyclovir and Cidofovir [9,11]. It has been shown that the
efficacy of the antiviral agent correlates better with its in
vitro index when applied topically in the presence of
DMSO or other penetrating agents [10].
Despite its usefulness, effects of DMSO itself on HSV-1 are
not well characterized. It has been reported that DMSO in-
duces viral reactivation both in the mouse ear model and
in explanted ganglia [12–16] and facilitates productive in-
fections of Vp16 negative strains [17]. For these reasons,
we considered it was of interest to describe the effect of
DMSO on parameters of HSV-1 replication during pro-
ductive infection and carried out a global analysis of the
effect of DMSO on HSV gene expression, utilizing our re-
cently developed micro-array system. Here we report that
DMSO was able to block productive infection in Vero cells
when administered after virus adsorption. DMSO seems
to cause this effect by acting at different sites with positive
cooperativity, as suggested by the Hill numbers of the in-
hibition curves. Accordingly, we show that DMSO inhib-
its HSV-1 viral DNA replication, reduces the stability of
the free virion, and also reduced the levels of a number of
viral transcripts. Interestingly, this reduction included
only a subset of early transcripts, which is a novel mode
for inhibiting the early phase of productive infection.
These results indicate that DMSO has the capacity to po-
tentiate the action of antiviral agents in vivo, not only by
enhancing their penetration, but also by affecting some vi-
ral functions.
Materials and methods
Cells and viruses
Rabbit skin fibroblasts were used to grow the virus and
Vero cells to analyze the action of DMSO and for plaque
assay. The analysis of gene transcription was carried out in
human foreskin fibroblasts (HFF). Rabbit skin fibroblast
and Vero cells were cultured in Eagle's minimum essential
medium (EMEM) containing 5% bovine serum and sup-
plemented with 100 U/ml penicillin and 100 µg/ml strep-
tomycin; HFF were cultured in EMEM containing 10%
fetal calf serum and 100 µ M G418. The cultures were
maintained at 37°C under 5% CO2.
In the experiments indicated, we used the recombinant vi-
rus HSV-1 (dUTPase/LAT) [18,19] containing the bacteri-
al β-galactosidase gene under the control of the dUTPase
promoter placed in the locus of the LAT gene virus. The
specific infectivity (plaque forming units per relative par-
ticle number) of these constructs is similar to the wild type
virus [20]. Vero cells cultures 90–100% confluent, in 24-
well plates (~105 cells/well) were infected with 1000 PFU
of this recombinant virus (multiplicity of infection of 0.01
PFU/cell). For these infections, the medium was removed
and the wells rinsed with saline. The cells were incubated
with 0.5 ml of virus suspension in PBS-glucose, for 1 h at
37°C with slow rocking. After this adsorption period, the
virus suspension was removed and replaced with overlay
medium (Eagle's minimum essential medium containing
5% fetal calf serum, supplemented with 0.34 mM arginine
100 U/ml penicillin and 100 µg/ml streptomycin). Incu-
bations were continued at 37°C until harvest.Page 2 of 10
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We have shown that the reporter β-galactosidase expres-
sion at 24 h p.i. is proportional to the number of PFU in
infections with a multiplicity of ≤0.1 [21], and, for con-
venience, we have used this rapid and accurate procedure
instead of a plaque assay to assess productive infection
where indicated in the results section. For this assay, the
medium was removed and the cells resuspended in 1.5 ml
of 10% sucrose in PBS, using a policeman. The suspension
was centrifuged at 2000 g for 10 min, the supernatant re-
moved and the cell pellet resuspended in 100 µl of fresh
10% sucrose in PBS. The cells were then permeabilized by
3 cycles of freeze thawing. Aliquots of 20–40 µl of these
suspensions were mixed with 0.4 ml of incubation buffer
(1.2 mM MgCl2, 60 mM KHP04, pH 7.8), and chlorophe-
nol red-β-galactopyranoside (Boeringer Mannheim) was
added to 5 mM final concentration. The reaction was al-
lowed to proceed for 10–30 min at room temperature and
stopped by adding 200 µl of 20% lactose. Product forma-
tion was evaluated by measuring absorbency at 550 nm.
Cytotoxicity assay
The cytotoxic effect of DMSO (Sigma or Fisher) treatment
on Vero cells was evaluated by the method of sulforhod-
amin B (SRB) [22,23]. Cells in 96-well plates were treated
with different concentrations of DMSO for either 8 or 24
h. After the treatment, the wells were washed three times
with saline and fresh medium was added. Forty eight hr
after the initiation of the treatment with DMSO cells were
fixed with 10% trichloroacetic acid (TCA) for 30 min at
room temperature (RT). TCA was washed and the wells
were dried overnight at RT. The cells were stained with 4%
SRB in 1% acetic acid for 30 min at RT, washed with 1%
acetic acid and dried overnight. SRB was extracted with 0.2
ml of 1 mM Tris Base and the densitometry read at 520
nm in an ELISA reader. Values were expressed as percent
of controls from untreated wells in the same plate.
DNA extraction
DNA was extracted as described previously [24] with some
modifications. To each well of infected cells in 24-well
plates with 0.6 ml of extraction buffer (25 mM EDTA, 100
mM NaCl, 1% SDS, 10 mM Tris pH 7.5) and 50 µl of pro-
teinase K solution (15 mg/ml) were added and then they
were incubated overnight at 48°C. The DNA solution was
extracted three times with phenol-chloroform (1:1) and
once more with chloroform. The DNA was precipitated
with ethanol overnight and pelleted by centrifugation.
The pellet was washed once with 70% ethanol, air-dried
and dissolved in 200 µl of water.
Analysis of the relative amounts of viral DNA by PCR
For this analysis we have used a semi-quantitative radio-
active PCR procedure previously described [21,24]. This
procedure is able to detect 1 pg of purified HSV-1 DNA
when using a plasmid preparation containing a fragment
of the VP5 gene. When purified viral DNA is mixed with
uninfected ganglia it is possible to detect less than 1000
viral genomes. Thus, the approach is able to detect the vi-
ral DNA and RNA-after conversion to cDNA-generated by
a single infected cell. To normalize signals for the recovery
of DNA, an actin primer set is used to amplify cellular sig-
nals. The ratio of both signals is determined by densitom-
etry.
Amplification by PCR was carried out as previously de-
scribed [24,25], using the following primer sets (sense/an-
tisense strand): VP5 (149-bp product), 5'-
TGAACCCCAGCCCCAGAAACC-3'/5'-CGAGTAAACCAT-
GTTAAGGACC-3'; rabbit actin (110-bp product) 5'-AA-
GATCTGGCACCACACCTT-3'/5'-
CGAACATGATCTGGGTCATC-3'. The reactions were car-
ried out in M.J. Research thermal cycler as follows: dena-
turation, 94°C for 30 sec; annealing, 55°C for 30 sec; and
extension, 60 s at 72°C. The final cycle was terminated
with a 10-min extension step. The products were made ra-
dioactive for autoradiography and image quantitation by
addition of 0.2µC of [α-32P]dCTP. For each reaction we
used 20 µl (10%) of the DNA sample, and the final vol-
ume of the reaction was 100 µl. One fifth of the amplified
product (corresponding to 2% of the original material)
was fractionated on 6% polyacrylamide gels in Tris-bo-
rate-EDTA. The PCR signals were visualized by scanning
an appropriately exposed autoradiogram by use of a Desk-
can II scanner (Hewlett-Packard). The signals were quan-
tified by densitometry using IP Lab Gel software (Signal
Analysis Corporation) in accordance with operational in-
structions.
RNA preparation and cDNA synthesis
For the preparation of total RNA from infected cells and
mock-infected cells we followed procedures previously
described [26]. For each preparation of RNA, 2 confluent
8 cm dishes of human fibroblasts were used. Virus adsorp-
tion was carried out for 30 min in 10 ml of PBS-10% glu-
cose and then replaced for fibroblast medium in the
presence or absence of 4% DMSO, and infection was con-
tinued for 6 h. Total RNA was extracted using the Trizol
procedure (GIBCO-BRL). Poly A RNA was prepared from
total RNA using a magnetic beads procedure (PolyATract
mRNA isolation system IV, Promega). Typically, yields
were 1% of total RNA.
Fluorescent-labeled cDNA was prepared from 1 µg of po-
ly(A) RNA from infected and mock-infected cells using
SuperScrip II reverse transcriptase (Gibco-BRL) and ran-
dom hexamer primers. The nucleotide concentrations in
the reaction were: 0.5 mM dGTP, dATP and dTTP, 0.3 mM
dCTP and 0.1 mM fluorescent nucleotide (Cy3-, Amer-
sham). Fluorescent-labeled cDNA was purified by filtra-Page 3 of 10
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(Amicon); then heat denatured for 2 min at 99°C, incu-
bated for 20–30 min at 37°C and centrifuged 2 min at
140,000 × g (to remove any solid impurity). Hybridiza-
tion to the micro-array [27] was for at least 16 h at 68°C
in 15 µl of 5×SSC-0.2% SDS under a coverslip. After hy-
bridization, the micro-array slide assembly was washed
sequentially in 1×SSC-0.2% SDS, 0.1×SSC-0.2% SDS and
0.1×SSC for 5 min at room temperature and spun dry in a
low-speed centrifuge. Micro-arrays were scanned by using
a confocal laser scan system (Scan Array 4000, General
Scanning). Data were collected at 10 um/pixel 16 bits of
depth, using Quantarray software (General Scanning).
Data analysis
To determine the level of significance between treatments,
p values were calculated using two-tailed t-test assuming
unequal variances by using the Microsoft Excel program
Results
Non-cytotoxic levels of DMSO inhibit HSV-1 replication
In the course of studies on the effect of surfactants on HSV
replication, we noted that percentages of DMSO greater
than 0.2% resulted in significant decreases in yields of in-
fectious HSV in infected cultured cells. Accordingly, we
did a dose-response experiment to determine the details
of this effect (Figure 1). We determined the 50% inhibito-
ry concentration (IC50) to be 0.65% in Vero cells infected
at a multiplicity of infection of 10 PFU/cell when the cells
were incubated with various concentrations of DMSO in
the overlay medium for 24 following infection.
Since high concentrations of DMSO are known to be cyto-
toxic, it was possible that all or part of the effect of DMSO
on productive infections was a consequence of this toxic-
ity. For this reason, we analyzed the cell toxicity of DMSO
treatment for 24 hr, or for 8 (Figure 2) by the method of
sulforhodamine B [22,23]. Incubation with 5% DMSO for
24 hrs resulted in a mortality of about 20%, but there was
no significant effect observed at this concentration when
the treatment was carried out for only 8 hr.
In order to more fully characterize the effect of DMSO
treatment on virus replication, we utilized the approach
described in our studies on the effect of suramin on virus
spread [21]. As shown in that study, the measurement of
reporter β-galactosidase gene activity in a recombinant re-
porter virus where the indicator gene is controlled by the
HSV UL50 (dUTPase) promoter inserted into the LAT lo-
cus provides an excellent measure of virus replication as
long as the initial multiplicity of infection is low (≤ 0.1).
We found that DMSO was more efficient in blocking pro-
ductive infection when present after the adsorption phase
as follows (Figure 3). Cells were pretreated for 24 h before
adsorption with various concentrations of DMSO, infect-
ed at a multiplicity of 0.01 PFU cells with reporter virus,
and then reporter gene activity assayed at 24 hr following
overlay with normal medium. Parallel experiments were
carried out by having the same concentrations of DMSO
present during the 1 hr adsorption period or during 23 hr
Figure 1
Effect of DMSO in the productive infection of HSV-1. Cul-
tured Vero cells (105 cells in 24-well plates) were infected
with 1 million PFU of the dUTPase/LAT recombinant virus.
After 1 hr adsorption period, overlay medium was added
containing the indicated concentrations of DMSO. At 24 hr
post-infection, the cells were harvested and the virus yield
was determined by plaque assay. Data are the average ± SD
of 3 duplicate determinations.
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Figure 2
Cell toxicity of DMSO. Confluent cultures of Vero cells in
96-well plates were treated with the indicated concentra-
tions of DMSO for either 24 h (filled circles) or for 8 hr
(open circles) and cytotoxicity determined 28 hrs after the
initiation of the treatment. Results are average ± SD of 4
duplicated determinations.
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produced a reduction of 30% of productive infection at
4% DMSO; such a reduction results most likely from the
cell toxicity of DMSO demonstrated above. No significant
reduction of productive infection was observed when
DMSO was present only during the adsorption phase (ca
10% at 4% DMSO). However, when present after adsorp-
tion DMSO blocked productive infection as assayed by re-
porter gene expression with an IC50 = 2.06 ± 0.36 and a
Hill coefficient (NH) of 4.2 ± 0.2. A value of the NH>>1
suggests that DMSO acts at multiple sites with positive co-
operativity to inhibit productive infection [28].
We next determined the length of the treatment with
DMSO required to block productive infection (Figure 4).
In this experiment, DMSO was added to 4% concentra-
tion in overlay medium immediately after the adsorption
phase and replaced for overlay medium (without DMSO)
at the indicated times. At 24 hr, the level of productive in-
fection was determined by reporter gene activity assay. An
inhibition of 50% was achieved after 4–5 h treatment, and
an almost complete blockade of productive infection was
achieved when DMSO is present for the first 8 h after ad-
sorption.
Figure 3
Effect of DMSO treatment on productive infection at differ-
ent phases of infection. Cultured Vero cells (105 cells in 24-
well plates) were infected with 1000 pfu of the dUTPase/LAT
recombinant virus. Treatments were as follows: DMSO at
the indicated concentrations was present for 24 h before
adsorption (filled circles), during the adsorption phase (open
circles) or for 23 hr after the adsorption period (filled trian-
gles). Also included is the effect of DMSO present for 23 hr
after adsorption on HFF cells infected under similar condi-
tions (open triangles). Reporter gene activity was determined
at 24 hr following infection. Data are the average ± SD of 3–
6 duplicate determinations.
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Figure 4
Time course dependency of DMSO blockade of productive
infection. Cultured Vero cells (105 cells in 24-well plates)
were infected with 1000 PFU of the dUTPase/LAT recom-
binant virus. After the adsorption phase, 4% DMSO was
added in the ovelay medium and kept for the indicated time
periods. At those times, the media were replaced with fresh
overlay medium without DMSO and the incubation contin-
ued 24 hr. Reporter gene activity was determined at 24 hr
post-infection. Data are the average ± SD of 3–6 duplicate
determinations.
Figure 5
Effect of 8 hr treatment of DMSO at different phases of infec-
tion. Cultured Vero cells (105 cells in 24-well plates) were
infected with 1000 PFU of the dUTPase/LAT recombinant
virus. Treatments were as follows: DMSO at the indicated
concentrations were present for 8 h before adsorption (filled
circles), 8 h immediately after adsorption (open circles) and
16 to 24 hr (triangles). Reporter gene activity was deter-
mined at 24 pi. Data are the averages ± S.D. of 3–6 duplicate
determinations.
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tically the same extent of blockade as the treatment for 23
h (compare Figures 1, 3, and 4) and this treatment has no
effect on cell toxicity, we more carefully analyzed the ef-
fect of DMSO treatment for 8 h (Figure 5). Cells were
treated for 8 hr with DMSO either before, immediately af-
ter adsorption or 15 h later (from 16 to 24 hr following in-
fection). The 8 hr pretreatment with DMSO demonstrated
no effect on productive infection as assayed by reporter
gene expression. Rather, there was a small stimulation of
productive infection, which was clear at concentrations
above 4% of DMSO; however, we do not consider that the
extent of this stimulation is biologically relevant. When
the treatment was carried out immediately after adsorp-
tion, the values for IC50 (2.34 ± 0.36%) and NH (4.1 ±
0.5) were not significantly different from those obtained
when the treatment was carried out for 23 h (p = 0.163,
Figure 3). However, when DMSO treatment was started at
15 h after adsorption, the value of the IC50 (2.89 ± 0.15%)
was somewhat higher. Although small, this difference is
statistically significant (p = 0.028) with respect to the 23 h
treatment. The value of NH was somewhat smaller (3.2 ±
0.7), but this difference was not significant.
DMSO inhibits HSV-1 replication by several mechanisms
To get some insight on the mechanism of DMSO inhibi-
tion of HSV-1 productive infection, we studied the action
of DMSO on the infectivity free HSV-1 virions, viral ge-
nome replication, and global patterns of transcription.
In order to assess the action of DMSO on free virion infec-
tivity, we incubated semi-purified preparations of cell-free
reporter virus at 37°C in the presence of different concen-
trations of DMSO for 7 hr followed by infection of Vero
cells at a multiplicity of 0.01 PFU/cell via adsorption for 1
h in the presence of DMSO. Infected cells were then incu-
bated for 24 hrs and reporter gene activity assayed. As
shown in Figure 6, the IC50 was found to be 0.95 ± 0.10%
with an NH not different from 1. Such a result suggests
that virion inactivation is only one component of the
overall inhibition of virus replication detailed in the pre-
vious section.
We next analyzed the action of DMSO on HSV-1 DNA
replication utilizing a semi-quantitative PCR procedure
[21,24,25]. We measured the relative ratio of HSV-1 to cel-
lular DNA at various times post infection in the presence
and absence of 4% DMSO (Figure 7). Viral DNA was am-
plified using a specific primer set for the gene of VP5 pro-
tein. To normalize for the recovery of DNA in the
extraction, cellular DNA was amplified with a primer set
specific for the actin gene. In the control infection viral
DNA increase in relative abundance (viral DNA over cell
DNA) is considerable by six hr following infection with
0.01 PFU per Vero cell. In contrast, in the presence of 4%
DMSO the increase in viral DNA levels, while substantial,
was clearly smaller than in the control. We, thus, conclud-
ed that DMSO partially blocks viral DNA replication
Our recent development of an oligonucleotide-based
DNA microarray for assaying HSV transcription patterns
[6,27] afforded us the means to carry out a global analysis
of the effect of 4% DMSO on the levels of viral mRNAs.
Since we found that the treatment has an effect on viral
DNA replication, we compared it to the effect of the pres-
ence of 300 µg/ml PAA treatment – a treatment known to
cause >99% inhibition of viral DNA replication [29]. Our
analysis of viral transcription was studied in human fore-
skin fibroblasts; because our micro-array contains only
human cellular probes, we used these cells instead of Vero
cells in order to be able to gauge the effect of DMSO treat-
ment on selected cellular transcripts. As shown in Figure
3, we determined that the inhibition of productive infec-
tion at a multiplicity of 0.01 PFU/cell by DMSO in these
cells was similar to that observed in Vero cells (IC50= 1.4
± 0.5, NH = 3.1 ± 0.65). Treatment of HFF cells with 4%
DMSO for 8 h caused no significant cell mortality (99 ±
6% survival, n = 8) when the treatment was for 8 h, but it
had some cytotoxic effect when the treatment was for 24
h (60 ± 4% survival, n = 8). Thus, transcription analysis
was carried out for a 6 h DMSO treatment.
Figure 6
Inactivation of HSV-1 virion infectivity by DMSO. The dUT-
Pase/LAT recombinant virus was suspended in PBS-glucose
medium at 2000 PFU/ml and incubated at 37°C for 7 hr. Aliq-
uots of 0.5 ml of the suspension were then adsorbed to Vero
cells (105 cells in 24-well plates) for 1 hr. The virus suspen-
sion was then replaced with overlay medium, and reporter
gene activity was determined at 24 hr. Data are the averages
± S.D of 4 duplicate determinations.
0 1 2 3 4 5
0
20
40
80
100
60
DMSO (%)
%
 R
ep
or
te
r 
G
en
e 
A
ct
iv
ityPage 6 of 10
(page number not for citation purposes)
BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/9For analyzing the transcription, infection was carried out
at a multiplicity of infection of 1 PFU/cell, DMSO or PAA
added following virus adsorption, and RNA isolated 6 hr
after the 1 hr adsorption period. Poly(A) containing RNA
was purified, and cDNA synthesized using Cy3-flouresen-
cent dye tagged dCTP. We carried out three replicate hy-
bridizations of each treatment regimen and normalized
the total HSV-1 specific fluorescence signal to the 75th per-
centile value for each experiment. Results are shown in Ta-
ble 1 (Additional File); those transcripts uniquely
resolvable with this chip are indicated. The level of most
HSV-1 transcripts was significantly reduced when 4%
DMSO is present during the infection. Levels of reduction
varies between none to 12-fold, and while this inhibition
was not selective for any specific kinetic class, great reduc-
tions were found in some genes coding for structural pro-
teins and virion assembly (major capsid protein–UL18/
20; capsomer tips–UL35, virion maturation – UL21, and
the gB/maturational protease family – UL27/28). The four
immediate early genes that can be uniquely resolved
(ICP0, ICP4, ICP27–UL54, and ICP22–US1) were not sig-
nificantly affected.
This pattern of inhibition was similar but clearly different
to that seen when PAA was used to inhibit viral DNA rep-
lication. Expectedly, a number of kinetically late tran-
scripts were more markedly reduced in the presence of the
DNA synthesis inhibitor. Here, and in a previous paper
[27]) we observed that PAA reduces the level of some early
genes. This seems to contradict the observation that only
some late, but not early protein synthesis is blocked by
PAA [29]. This can be attributed to different experimental
conditions, such as a MOI = 50 in that report. In fact, at
MOI = 2 a reduction in the level of ICP0 transcript was re-
ported [30]. Three early transcripts, the ribonucleotide re-
ductase family (UL39/40), dUTPase (UL50), and the UL56
pathogenesis gene were greatly inhibited by DMSO treat-
ment while being relatively unaffected by the inhibition
of viral DNA replication by PAA. This was not seen with
the thymidine kinase transcript (UL23). Finally, three im-
mediate early transcripts, which show a marked reduction
in the presence of 300 µg/ml PAA for 6 hr as compared to
the control were not affected to anywhere near as great a
degree with DMSO treatment (ICP27–UL54, ICP0,
ICP22–Us1). The blockade of early transcripts clearly
demonstrates that the reduction of transcripts levels by
DMSO treatment and not solely due to its significant in-
hibition of viral DNA (Figure 7).
We analyzed a set of cellular transcripts known to be in-
volved in the stress response under these various condi-
tions of infection. We found that upon comparison of
mock infected samples; DMSO did not alter significantly
the level of any cellular transcript included on the current
chip whose signal was equal to or above the SSC back-
ground (ca 500 units) (data not shown). When we com-
Figure 7
PCR analysis of HSV-1 DNA replication in the presence or absence of DMSO. Total DNA was isolated from cultures of Vero
cells infected with 1000 PFU of the dUTPase/LAT recombinant and the indicated hrs post-infection and amplified in the condi-
tions described in Material and Methods. Aliquots of the amplified products were fractionated in 6% polyacrylamide gels in
Tris-borate-EDTA and evaluated by densitometry.Page 7 of 10
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following the control infection vs the DMSO treatment,
we found that the expression of four cellular genes (Acti-
vating transcription factor 3(ATF3), Human cyclin B, FOS
like antigen 1 (FRA-1), and JunBta) showed a signficantly
different level of expression in DMSO treated cells as com-
pared to infected control cells. Thus, ATF3 median level
was 172 (S.D. 1095) units in untreated vs 9747 (S.D.
3863) in DMSO (p = 0.04); CyclinB control median 361
(S.D. 228) vs 1427 (S.D. 495) in DMSO (p = 0.03); FRA-
1 control median 1749 (S.D. 1277) vs 12,380 (S.D. 3778)
in DMSO (p-0.03); and, JunBta control median 3504
(S.D. 5468) vs 33,986 (S.D. 1535) in DMSO (p = 0.01).
These data suggest that the effects of an early block on
HSV gene expression might be related to changes in cellu-
lar factors. However, the biological significance of the dif-
ferences detected in the study is unclear at this time.
Discussion
Our results show that DMSO blocks productive infection
of HSV-1 in cultured cells. The dose-response curves of the
blockade have a Hill coefficient (NH) greater than three,
indicating that DMSO exerts its effect by acting at different
points of the productive infection cycle with high positive
cooperativity [28]. In agreement with such an interpreta-
tion, we observed that DMSO inactivated free virions,
blocked expression of specific HSV-1 transcripts, inhibited
viral DNA replication, and affected the virus-induced
shut-off of expression of four cellular genes. All these ac-
tions are observed at conditions in which DMSO does not
have any significant cytotoxic action.
The observation that 50% inhibitory concentration of
DMSO is significantly below the cytotoxic concentration
suggest that DMSO may have a specific inhibitory activity.
Evidence in strong support for a specific action of DMSO
was uncovered in experiments based on global transcrip-
tional analysis using our recently described oligonucle-
otide-based DNA microarray provided us with a powerful
tool to dissect some of the effects of DMSO on viral gene
expression. As shown in Table I, DMSO reduces the level
of transcription of many HSV-1 genes, and the reductions
is not solely a result of a general inhibition of viral DNA
synthesis since there are some marked differences in the
pattern of transcript abundance seen in the presence of
300 µg/ml PAA as compared to 4% DMSO. Interestingly,
the levels of the immediate early genes involved in the reg-
ulation of other viral genes (ICP0, ICP4 and ICP27) were
not appreciably affected, while, and in contrast, the largest
reductions in transcript levels (over 7-fold) were generally
found in genes coding for structural proteins. This points
to the possibility that DMSO blocks the maturation of vir-
ions.
DMSO showed a previously unappreciated manner of in-
hibiting early phase of HSV-1 productive infection, as it
inhibited some but not all early transcripts. Some of these
early transcripts such as ribonucleotide-reductase (UL39)
and dUTPase (UL50) are strongly inhibited. This inhibi-
tion may have a role in the reduced viral DNA replication
seen upon DMSO treatment.
Most of the eighty-odd cellular transcripts on the DNA
microarray [27] used in these experiments do not provide
sufficiently strong signals with infected cell RNA to allow
statistically reliable analysis [6]. Still, it is interesting that
four cellular transcripts (Activating transcription factor 3,
Human cyclin B, FOS like antigen 1 and JunBta) were sig-
nificantly increased in DMSO-treated infected cells. While
potentially interesting, these results are not of sufficient
breadth to indicate whether alterations of cellular func-
tions are a factor in the overall inhibition of viral replica-
tion.
Conclusion
Our results show that DMSO can block HSV-1 productive
infection in vitro. As shown by a Hill coefficient greater
than 1, the mechanism of this blockade is complex, with
DMSO altering several temporally distinct viral functions.
In vivo, DMSO has been shown to enhance the effect of
several antivirals. This effect has been attributed to the
ability of DMSO to penetrate the skin [10]. The results of
this study suggests the possibility that DMSO may also
further enhance antiviral activity through a previously un-
disclosed inhibitory action.
List of abbreviations
DMSO: dimethyl sulfoxide
EMEM: Eagle's minimum essential medium
HFF: Human foreskin fibroblast
PBS: Phosphate buffer saline
PCR; Polymerase chain reaction
SBR: Sulforhodamin B
HSV-1: Herpes simplex virus-1
Author's contributions
Author 1 (JSA): Conceived of the study, carried out the ex-
periments on productive infection levels, cytotoxicity,
PCR and micro-array analysis, and drafted the manu-
script.
Author 2 (DR): Fabricated micro-array and participated in
its design.Page 8 of 10
(page number not for citation purposes)
BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/9Author 3(PG): Participated in analysis of microarray data,
experiment design, and manuscript writing.
Author 4 (EKW): Laboratory sponsor who conceived and
coordinated the overall study. Performed data analysis,
designed the HSV-1 specific micro-array, and wrote the fi-
nal version of the manuscript. Participated in experiment
design
Competing interests
None declared.
Acknowledgements
This work was supported by grants CA11861 and 90287 (EKW) from the 
National Cancer Institute and BBSRC (PG). JSA was the recipient of a UCI 
Faculty Career Development Award. We thank M.K. Rice for valuable as-
sistance, Alan Ross for assistance in microarray fabrication and S.W. Sting-
ley, P. Lieu and G.B. Devi-Rao for helpful discussion.
References
1. Whitley RJ, Soong SJ, Dolin R, Galasso GJ, Chien LT, Alford CA: Ad-
enine arabinoside therapy of biopsy-proved herpes simplex
encephalitis. National Institute of Allergy and Infectious Dis-
eases collaborative antiviral study. N. Engl. J. Med. 1977,
297:289-294
2. Wagner EK, Bloom DC: Experimental investigation of herpes
simplex virus latency. Clin Microbiol Rev 1997, Jul 10:419-443
3. Corey L, Spear PG: Infectious with herpes simplex viruses (1).
N. Engl. J. Med. 1986, 314:686-691
4. Corey L, Spear PG: Infectious with herpes simplex viruses (2).
N. Engl. J. Med. 1986, 314:749-757
5. Nesburn AB: "Report of the Corneal Disease Panel: Vision Re-
search-A National Plan 1983–1987". 1986
6. Wagner EK, Garcia-Ramirez JJ, Aguilar JS, Stingley SW, Devi-Rao GB,
Ghazal P: Practical Approachs To Oligonucleotide-Based
DNA Microarray: Lessons From Herpes Virus. Prog. Nucleic Ac-
ids Res. 2002
7. Hamuy R, Berman B: Treatment of herpes simplex virus infec-
tions with topical antiviral agents. Eur. J. Dermatol. 1998, 8:310-
319
8. Spruance SL, Freeman DJ: Topical treatment of cutaneous her-
pes simplex virus infections. Antiviral Res. 1990, 14:305-321
9. Afouna MI, Mehta SC, Ghanem A-H, Higuchi WI, Kern ER, DeClercq
E, El-Shattawy HH: Influence of the treatment protocol upon in
vivo efficacy of Cidofovir (HPMP) and Acyclovir (ACV) J.
Pharm Sci. 1999, 88:530-534
10. Spruance SL, Stewart JCB, Freeman DJ, Brightman VJ, Cox JL, Wen-
erstrom G, McKeough MB, Rowe NH: Early application of topical
15% idoxuridine in dimethyl sulfoxide shortens the course of
herpes simplex labialis: A multicenter placebo-controlled
trial. J. Infect Dis. 1990, 161:191-197
11. Freeman DJ, Spruance SL: Efficacy of tropical treatments for
herpes simplex virus infections: predictions from an index of
drug characteristics in vitro. J. Infect Dis. 1986, 153:64-70
12. Bernstein DI, Kappes JC: Enhanced in vitro reactivation of la-
tent herpes simplex virus from neural and peripheral tissues
with hexamethylenebisacetamide. Arch. Virol. 1988, 99:57-65
13. Harbour DA, Hill TJ, Blyth WA: Recurrent herpes simplex in the
mouse: Inflammation in the skin and activation of virus in the
ganglia following peripheral stimulation. J. Gen. Virol. 1983,
64:1491-1498
14. Leib DA, Coen DM, Bogard CL, Hiks KA, Yager DR, Knipe DM, Tyler
KL, Schaffer PA: Immediate-early regulatary gene mutants de-
fine different stages in the establishment and reactivation of
herpes simplex virus latency. J. Virol. 1989, 63:759-768
15. Hill TJ, Blyth WA, Harbour DA, Berrie EL, Tullo AB: Latency and
other consequences of infection of the nervous system with
herpes simplex virus. Prog. Brain Res. 1983, 59:173-184
16. Whitby AJ, Blyth WA, Hill TJ: The effect of DNA hypomethylat-
ing agents on the reactviation of herpes simplex virus from
latently infected mouse ganglia in vitro. Arch. Virol. 1987,
97:137-144
17. McFarlene M, Dakis JI, Preston CM: Hexamethylene biscacrila-
mide stimulates herpes simplex virus immediate early gene
expression in the absence of trans-induction by Vmw65. J.
Gen. Virol. 1992, 73:285-292
18. Huang C-J, Goodart SA, Rice MK, Guzowski JF, Wagner EK: Muta-
tional analysis of sequences downstream of the TATA box of
the herpes simplex virus type 1 major capsid protein (VP5/
UL19) promoter. J. Virol. 1993, 67:5109-5116
19. Huang C-J, Rice MK, Devi-Rao GB, Wagner EK: The activity of the
psuedorabies virus latency-associated transcript promoter is
independent on its genomic location in herpes simplex virus
recombinants as well as on the type of cell infected. J. Virol.
1994, 68:1972-1976
20. Immergluck LD, Domowicz MS, Schwartz NB, Herold BC: Viral and
cellular requirements for entry of herpes simplex virus type
1 into primary neuronal cells. J. Gen. Virol. 1998, 79:549-559
21. Aguilar JS, Rice M, Wagner EK: The polysulfonate compound
suramine blocks adsorption and lateral diffusion of herpes
simplex virus Type-1 in Vero cells. Virology 1999, 258:141-151
22. Skehan P: Cytotoxic and cell growth assay. In "Cell Biology. A Lab-
oratory Handbook  (Edited by: JE Celis) Academic Press. San Diego 1998
23. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica DT,
Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cy-
totoxicity assay for anticancer-drung screening. J. Natl. Cancer
Inst. 1990, 82:1107-1112
24. Devi-Rao GB, Aguilar JS, Rice MK, Garza HH, Bloom DC, Hill JM,
Wagner EK: Herpes simplex virus genome replication and
transcription during induced reactivation in rabbit eye. J. Virol.
1997, 71:7039-7047
25. Devi-Rao GB HH, Bloom DC, Stevens JG, Wagner EK: Herpes sim-
plex virus replication and gene expression during explant in-
duced reactivation of latently infected murine sensory
ganglia. J. Virol. 1994, 68:1271-1282
26. Lieu PT, Wagner EK: The kinetics of VP5 mRNA expression is
not critical for viral replication in cultured cells J. Virol. 2000,
74:2770-2776
27. Stingley SW, Garcia-Ramirez JJ, Aguilar JS, Simmen K, Sandri-Goldin
RM, Ghazal PH, Wagner EK: Global analysis of HSV type 1 Tran-
scription using an Oligonucleotide-based DNA Microarray. J.
Virol. 2000, 74:9916-9927
28. Dahlquist FW: The meaning of Scatchard and Hill plots. Meth-
ods Enzymol. 1978, 48:270-299
29. Honess RW, Watson DH: Herpes symplex virus resistance and
sensitivity to phosphonoacetic acid. J. Virol. 1977, 21:584-600
30. Schang LM, Rosember M, Schaffer PA: Roscovitine, a specific in-
hibitor of cellular cyclin-dependent kinases, inhibits herpes
simplex DNA synthesis in the presence of viral early pro-
teins. J. Virol. 2000, 74:2107-2120
31. Wagner EK: Herpes simplex virus–Molecular Biology. in Ency-
clopedia of Virology  (Edited by: A Granoff, RG Webster) Academic Press,
London 1999, 686-696
32. Glanz SA: Primer of Biostatistics. McGraw Hill, New York 1997
Additional material
Additional File
HSV-1 Transcript Abundance in the Presence or Absence of 4% DMSO 
or 300 µg/ml PAA at 6 hr post infection with HSV-1. Table 1: contains 
the signal intensities for each of the HSV-1 transcripts, indicating their 
kinetic class, and the levels of significance of their difference from the con-
trol.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2334-2-9-S1.doc]Page 9 of 10
(page number not for citation purposes)
BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/9Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/2/9/prepub
Publish with BioMed Central  and  every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.comPage 10 of 10
(page number not for citation purposes)
